

**Formulation of Extended Release
Theophylline Tablets –
experimental, modelling and
bio-equivalence studies**

by

Kamal Kumara Gamini Mahendranath Parakrama

Bandara Herath

Ph. D.

2004

**Formulation of Extended Release
Theophylline Tablets – experimental,
modelling and bio-equivalence studies**

by

Kamal Kumara Gamini Mahendranath Parakrama

Bandara Herath

**Thesis submitted to the University of Sri Jayawardenepura, for
the award of the Degree of Doctor of Philosophy in Chemistry
(Pharmaceutics) on 30th July 2004.**

The work described in this thesis was carried out by me under the supervision of
Prof. A. M. Abeysekera (B.Sc., Ph.D.) Department of Chemistry, University of
Sri Jayawardenepura

And

Dr. Anil K. E. Goonethilleke (MBBS, MD, MRCP) Department of Pharmacology,
University of Sri Jayawardenepura)

And a report on this thesis has not been submitted in whole or in part to any other
University for another degree / Diploma.



K.K.G.M.P.B. Herath. BA (Chemistry - major, Biology - minor) Wartburg
College, USA, MSc. (Organic Chemistry) Iowa state University, Ames, IA, USA.

We certify that the above statement made by the candidate is true and that this thesis is suitable for submission to the University for the purpose of evaluation.



Dr. Anil K.E. Goonethilleke,
Department of Pharmacology,
Faculty of Medical Sciences,
University of Sri Jayawardenepura



Prof. A. M. Abeysekera ,
Department of Chemistry,
Faculty of Applied Sciences,
University of Sri Jayawardenepura)



Table of contents

Contents	Page numbers
<i>Title page</i>	
Table of Contents	<i>i-vi</i>
<i>List of Tables and Figures</i>	<i>vii-xii</i>
<i>Acknowledgement</i>	<i>xiii-xiv</i>
<i>Abbreviations</i>	<i>xv</i>
<i>Abstract</i>	<i>xvi-xviii</i>
1. Introduction	1
1.1 Theophylline	3
1.2 Use and pharmacological aspects of theophylline	3
1.3 Pharmacokinetics to model <i>in-vivo</i> requirements	7
1.4 Biological factors considered in selecting theophylline as an oral extended release dosage	11
1.5 Release rate controlling techniques used in oral extended-release dosage forms	11
1.6 Theoretical models of drug release	16
1.7 Chemical stability of theophylline and formulation methodology	23

1.8	Compounds of theophylline employed in formulations	24
1.9	Clinical studies - bioavailability and bioequivalence	25
1.10	Objectives of the thesis	31
2.0	Materials and Methods	
2.1	Materials	32
2.2	Apparatus	33
2.3	Analysis of Theophylline Anhydrous raw materials	34
2.4	Preparation of the blends	36
2.5	Blend property measurements	36
2.6	Compression of the tablets	37
2.7	In-process control	39
2.8	Quality Control Protocol For Theophylline Tablets	40
2.9	Stability studies	40
2.10	Packaging and storage	42
2.11	Measurement of eroding rate of tablets	43
2.12	Bio-Equivalence Study Protocol	43

3.0 Results	46
Table 1 Intrinsic dissolution of theophylline raw material	46
Table 2 Particle size distribution of final blend for Theophylline extended release	48
Table 3 Moisture of the final blend for Theophylline extended release tablets	48
Table 4 Individual tablet weights and dissolution of 3 separate lots with Formula no. FD00M01 in Table 22	49
Figure 6 Running chart of weight difference of tablets with time graph	50
Table 5 Diameter of the Tablets in 3 different lots	51
Table 6 Thickness of the Tablets	51
Table 7 Hardness of Tablets from 3 lots of 125mg strength	51
Table 8 Hardness of Tablets from 3 lots of 300mg strength	52
Table 9 Friability of Tablets from 3 lots of 125 mg strength	52
Table 10 Friability of Tablets from 3 lots of 300mg strength	52
Table 11 Drug release results of theophylline tablets ER 300mg— Actual results are given below at time points for 3 lots.	53
Table 12 Assay of Theophylline tablets 125 mg	54
Table 13 Accelerated stability test results of theophylline ER 125mg tablets stored at 60°C	55

Table 14	Measurement of eroding rate of Tablets	55
----------	--	----

Table 15	Dissolution rate of 4 modified release tablets	56
----------	--	----

available in the Sri Lankan market.

Table 16	Dissolution profiles of the Nuline 250 SR tablets and	56
----------	---	----

SPMC-Theophylline extended release tablets, two of 125mg

(Total 250 mg strength), in pH 2.0 and 7.4 dissolution media

Table 17	Demographic data of subjects participated for the	57
----------	---	----

bio equivalence study regarding age, weight, height and

history of asthma

Table 18	Demographic data regarding the smoking, allergy,	58
----------	--	----

and concurrent medication the subjects participated

in the bio-equivalence study

Table 19	Theophylline concentration in blood serum	59
----------	---	----

4.0 Discussion

4.0	Introduction	60
-----	--------------	----

4.1	Development of theophylline extended release formulations	60
-----	--	----

4.1.1	Formulation Design	60
-------	--------------------	----

4.1.2 Formulation Development of theophylline extended release tablets	74
4.1.3 Summary of extended release formulation development	88
4.2 Modelling Bio-erodible Tablet as a Dissolution and Diffusion Controlled System	89
4.2.1 Mathematical modelling	89
4.2.2 Selection of the form of diffusion coefficient for spherical tablet using experimental data	93
4.2.3 Derivation of equations for a cylindrical tablet	99
4.2.4 A general form of dissolution formula to be used with both spherical and cylindrical tablets	103
Generalizing the dissolution formula	105
4.2.5 Summary of Modelling Bio-erodible Tablet	114
4.3 Bioequivalence Study	115
4.3.0 Introduction	115
4.3.1 Purpose of the Study	115
4.3.2 In-vitro and in-vivo study of commercially available products	115
4.3.3 Drug administration and the blood sample collection	123
4.3.4 Results of the bioequivalence study	125
4.3.5 Summary of the bioequivalence study	131

5.0 Quality Control Protocol			132
5.0 Introduction			132
5.1 Quality Control Protocol of Theophylline extended release tablets			134
5.2 Summery of Quality Control Protocol			142
Conclusion			143
List of References			147-157
Appendices	Appendix	I	1-06
	Appendix	II	1-24
	Appendix	III	1-17
	Appendix	IV	1-20

List of Tables and Figures

Page No

Fig. 1	Serum drug level versus time	10
Fig. 2	Dissolution controlled drug delivery system in beads	12
Fig. 3	Diffusion controlled drug delivery system	13
Fig. 4	Bio-erodable matrix system	14
Fig. 5	Osmotic Control Drug delivery Systems	16
Table 1	Intrinsic dissolution of theophylline raw material	46
Table 2	Particle size distribution of final blend for Theophylline extended release	48
Table 3	Moisture of the final blend for Theophylline extended release tablets	48
Table 4	Individual tablet weights and dissolution ratio with formula No. FD00M01 (given in Table 22) of 3 separate lots	50
Fig. 6	Running chart of weight difference of tablets with time graph	
Table 5	Diameter of the Tablets in 3 different lots	51
Table 6	Thickness of the Tablets	51
Table 7	Hardness of Tablets from 3 lots of 125mg strength	51
Table 8	Hardness of Tablets from 3 lots of 300mg strength	52

Table 9	Friability of Tablets from 3 lots of 125 mg strength	52
Table 10	Friability of Tablets from 3 lots of 300mg strength	52
Table 11	Drug release results of theophylline tablets ER 300mg— Actual results are given below at time points for 3 lots.	53
Table 12	Assay of Theophylline tablets 125 mg	54
Table 13	Accelerated stability test results of theophylline ER 125mg tablets stored at 60°C	55
Table 14	Measurement of eroding rate of Tablets	55
Table 15	Dissolution rate of 4 modified release tablets and a conventional tablet available in the Sri Lankan market.	56
	The Test method used was USP dissolution apparatus 2, pH 4.5 phosphate buffer at 37°C.	
Table 16	Dissolution profiles of the Nuline 250 SR tablets and SPMC-Theophylline 2 of 125 mg (Total of 250 mg strength) with pH 2.0 and 7.4 of the dissolution media over 8 hour.	56
Table 17	Demographic data of subjects participated for the bio equivalence study regarding age, weight, height and history of asthma	57
Table 18	Demographic data regarding the smoking, allergy, and concurrent medication the subjects participated in the bio-equivalence study	58
Table 19	Theophylline concentration in blood serum	59

Fig. 7	Eudragit® RSPO ; (I) ammonio methacrylate copolymer	67
Table 20	Chemical and Physical Properties of methacrylate ester copolymers	68
Table 21	Chemical and Physical Properties of methacrylic acid Copolymers	69
Fig. 8	Dissolution profiles of methacrylic acid copolymers	70
Fig. 9	DQP.M ; (II) Diaryl quaternaryammonium phosphinic acid metal Complex	71
Fig. 10	Receptor DQP.M; (II) binds with electron rich 2 –naphthoxyacetate	72
Table 22	The formulations with varied amount of resin per Theophylline Extended Release tablets and their drug release profile of formulations	75
Table 23	The formulations with varied amount of resin per tablet	78
Table 24	Two formulations of theophylline tablets where one has Amino Methacrylate copolymer (Eudragit® RSPO) and the other has Amino Methacrylic acid copolymer (Eudragit® S-100) as the retardant	79
Fig. no. 12	Effect of pH on drug release of theophylline extended release tablets with Eudragit® RSPO without filler excipients	80
Fig. no. 13	Effect of pH on Drug Release of Theophylline Extended Release Tablets with Eudragit S -100 polymer and with out filler Excipient	81
Fig. no. 14	Intrinsic dissolution of 4 raw material consignments of	83-84

3 manufacturers

Table 25	Effect of pH on Drug Release of Theophylline Extended Release Tablets with same formula but with different filler Excipient	88
Fig. 15	Variation of D_c with the percentage of retarding agent for different C values for the relation given by equation (2)	91
Fig. 16	Variation of D_c with the percentage of retarding agent for different C values for the relation given by equation (3)	92
Table 26	D_r for different times at different X values	95
Fig. 17	Predicted dissolution ratios for different retarding agent value compared with observations for equation (6) using different 'c' and ' α ' coefficients	96
Fig. 18	Predicted dissolution ratios for different retarding agent value compared with observations for equation (6) using common 'c' and ' α ' coefficients.	97
Fig. 19	Predicted dissolution ratios for different retarding agent value compared with observations for equation (7) for different 'c' and ' α ' parameters	98
Fig. 20	Predicted dissolution ratios for different retarding agent value compared with observations for equation (7) for common 'C' = 0.3703 and ' α ' = 0.50868 parameters	98
Fig. 21	The relation of tablet radius to the tablet height	102

Table 27	Dissolution ratio for the experiment FD02E02	102
Fig. 22	The best fit function from the cylindrical formula compared with the experimental data for the experiment No. FD02E02	103
Fig. 23	The description of the experiment FD02E02 of cylindrical tablet using the spherical tablet formula using the 'equivalent radius' concept	103
Table 28	Dissolution ratio for the experiments used in generalization	106
Fig. 24	Comparison of the FD01K07 experimental data with estimation from the optimized formula for the cylindrical tablet given in equation (20)	108
Fig. 25	Comparison of the FD01K07 experimental data with estimation from the optimized formula for the spherical tablet given in equation (21)	108
Fig. 26	Comparison of the GD02E02 experimental data with estimation from the optimized formula for the cylindrical tablet given in equation (22)	109
Fig. 27	Comparison of the GD02E02 experimental data with estimation from the optimized formula for the spherical tablet given in equation (23)	110
Table 29	Optimized parameters for the two experiments corresponding to two formulae	111
Fig. 28	Comparison of observations with generalized equation Predictions	112
Fig. no.29	Comparison of predictions against observations for GB class of materials expressed by the general equation (25)	113

Table 30	Comparison of retail prices of various brands of imported theophylline SR with the Proposed prices of SPMC-Theophylline ER Tablets as at June 30. 2003	116
Fig. No. 30	Dissolution profiles of 4 controlled release commercially available theophylline preparations	117
Table 31	The Physical appearance and market information of the products discussed above are tabulated in this table for Quibron TSR, Unicontin, Neulin SR and Broncodil-XL (200).	120
Table 32	Dissolution profiles of the Neulin 250 SR tablets and SPMC-Theophylline 2 of 125 mg (Total of 250 mg strength) with varying pH of the dissolution media over 6 hours	123
Fig. 30	<i>Concentration averages of 20 volunteers of theophylline in serum with test SPMC [T] tab. and standard 3M (Neulin, Australia) [N] tab (tablets) for 24 hours.</i>	125
Table 33	Comparison study of weight variation of Theophylline ER 300mg tablets with USP	131
Fig. 31	Variation of the theophylline concentration in serum with time for test (SPMC) and Standard (Neuline) for subject 1 to 20.	

Annex IV 1-10

ACKNOWLEDGEMENT

Most of the research work of this PhD thesis was carried out at the State Pharmaceuticals Manufacturing Corporation (SPMC) of Sri Lanka, Ratmalana.

I wish to express my sincere gratitude to:

Dr. Anil Goonethilleke, Department of Pharmacology, University of Sri Jayawardenapura, my Guru, who taught me to set standards in the field, for all his support and for never losing faith in my ability to complete this thesis. I am also grateful for his ability to turn my pessimism into moment of optimism.

Prof. A M Abeysekera, Dean, Faculty of Applied Sciences., University of Sri Jayawardenapura for precise guidance and valuable comments on manuscript. He was an inspiration to me through out the work.

Former Chairmen of SPMC Prof. Colvin Gunaratna, Mr. K A T B Jayawardena, Dr. Athula Kahandaliyanage, Mr. N Kiriella, Mr. K M S B Rekogama, and present Chairman Mr. G Y A Ravindra Jayananda, along with the respective Board of Directors for encouraging me to do research and allocating funds.

I would like to thank all Senior Managers of SPMC Mr. G. Karunapala, Mr. W. Pathirana, Mr. A.Kuruppu, Mr. S. Hewage, Mr. A. Gunarathna, and Mr. Brian Cooray, and the senior managers of the State Pharmaceuticals Corporation Mr. H.K. Sirisena, Mr. M. Kruppu, Ms Surangani and all the other SPMC Assistant Managers and Executives for their encouragement, for helpful discussions and support throughout the work.

Mr. Ajith Munisinghe, Ms. Hemanthi Rathnayaka, Mr. T A Y Wishvakeerthi, Mr. A P Sumith for all the support work in the Formulation Development Lab.

Dr. T.M.J. Munasinghe (MRI) for valuable discussions and “all ways ready to help” attitude. Dr. Kamal Gunatunage, University of Sri Jayawardanapura, for convincing patients to give blood samples, and collecting them. Dr. Preethi Zoysa, University of Colombo,

giving valuable advice in theophylline blood level analysis. My thanks are also to all the bio-equivalence study working group Dr. W.D.P.L. Wasalathanthri, Dr. N.H.Dharmatilake, and Dr. W.S.D. Chandrasiri for looking after the clinical side of the patients and having never failing in enthusiasm. I thank the entire crew in the "Health watch" for helping me in the Clinical Studies in various ways and specially Ms. Samantha and Ms. Tishari for collecting blood samples, doing liver function and other tests.

Professor D.A. Thanthirigoda, University of Sri Jayawardanapura, is also appreciated for the valuable discussions in the process of developing the mathematical model and the interest in my work.

I wish to thank all the State Pharmaceutical Manufacturing Corporation staff including the Quality Control staff for repeating analytical work, Production staff for scale-up trials and commercial scale work, Maintenance staff for maintaining the machinery and for new fabrications done, which helped my work, Planning and Procurement staff of the for supplying raw materials.

My gratitude goes to the entire volunteer group who participated in the Bio-equivalence study, for been patient, and trusting the newly developed product and my commitment to the project.

The State Pharmaceuticals Manufacturing Corporation for Financial support for the project, Health Watch (Pvt.) Ltd. Colombo, Sri Lanka, Hemas Pharmaceuticals (Pte) Ltd, Colombo 1, Sri Lanka, and Abbot diagnostics, Karachchi, Pakistan for Providing instruments and Chemicals

My wife Suleka, son Aroshana, brothers Prof. Sirkantha, Bandara, Kerthi Herath, and their wives Mrs. Sujatha Herath, Mrs. Cecil Herath my father-in-law Mr. Elmo de Silva and mother-in-law Mrs. Neomi De Silva for their support, tolerating my always busy schedules, and all helping me in many ways, to survive through the long years of study.

Last but not least that the driving force for the research study was from my beloved parents late Appachi Mr. K. B. Herath and late Amma Mrs. Malini Herath, thank you for always encouraging me to study.

ABBREVIATIONS

BA	bioavailability
bd	twice daily
BE	bioequivalence
tds	three times a day
BP	British Pharmacopoeia
BNF	British National Formulary
cGMP	current Good Manufacturing Practices
CRS	chemical reference standards
Dbc/S	double convex tablet with score mark embossed one side
GI	gastro intestine
GIT	gastro intestine tract
EUP	European Pharmacopoeia
Fb/S	Flat bevelled tablet with score mark embossed one side
FDA	Food and Drug Administration
HPLC	high performance liquid chromatography
Hr	Hour
Hrs	Hours
IP	Indian Pharmacopoeia
JP	Japanese Pharmacopoeia
min	minute
NLT	not less than
SPC	State Pharmaceuticals Corporation
SPMC	State Pharmaceuticals Manufacturing Corporation
TER	Theophylline Extended Release
WHO	World Health Organisation
USFDA	United States Food and Drug Administration

Formulation of Extended Release Theophylline Tablets
– experimental, modelling and bioequivalence studies
Kamal Kumara Gamini Mahendranath Parakrama Bandara Herarh

ABSTRACT

The objectives of this research project are to study the release behaviour of theophylline from the polymer matrices containing tablets, to develop an extended release theophylline formulation, to establish quality control standard specifications for the theophylline extended release tablet formulation, to scale-up the formulation for commercial manufacture, to develop a mathematical model to correlate release behaviour with the formulae, to identify the critical processes and to set manufacturing standards to ensure the reproducibility of theophylline extended release tablet formulation, to establish the bioequivalence of the formulation developed with a well prescribed preparation available in the Sri Lankan and international markets, and to market the new formulation commercially.

Extended release pharmaceutical formulations are complex, and are indicated specially in drugs having a narrow therapeutic window and a moderate half-life. The first chapter of this thesis describes studies carried out to understand the drug release behaviour of extended release formulations made from polymer matrices as applicable to theophylline, and the development of a theophylline extended release (modified or sustained release) formulation based on these studies. The selection of appropriate filler excipients was demonstrated to have a significant effect on the drug release properties of theophylline in a tablet matrices containing ammoniomethacrylate copolymer as the retarding agent. Theophylline tablets were manufactured to contain 50 to 94 percent of active ingredient, 15 to 0 percent filler excipient, and 2 to 15 percent matrices. The release rate of the drug was highest when microcrystalline cellulose was used, and slowest when calcium sulphate was used as the filler excipient, which is consistent with other reports^{79a,b}. It was observed that when maize starch is incorporated, the tablets disintegrated with high variation in release rates from tablet to tablet. The effect of the pH in drug release was tested and dissolution rates in phosphate buffer media at pH 6.8 and 7.4 were found to be much lower than at pH 4.5. Dissolution rates were higher in acidic media indicating that this is a factor when

calcium sulphate filler excipients are used. When no filler excipients are used dissolution rates were marginally higher or the same in near neutral pH media (pH 6.8 to 7.4 phosphate buffer) compared to the dissolution in acidic media (pH 4.5 phosphate buffer).

Ammoniomethacrylate Copolymer (Eudragit® RS-PO) was selected as the retardant, and three strengths of theophylline extended release formulations were developed; namely 125 mg (paediatric strength), 250 mg and 300mg (adult strengths). The stability of the new formulations were tested under accelerated and ambient conditions for two years, and the shelf life of the packed product was confirmed for two years under ambient tropical conditions in Sri Lanka.

Quality control standards for theophylline extended release tablets were established, for appearance, identification, physical strength, uniformity of dosage form, drug release rate and potency, using the available standards for other similar formulae with slight modifications where appropriate.

The drug release mechanism of the tablet developed, in this study can be described as mainly dissolution rate controlling mechanism though diffusion controlled mechanism could be expected. Recognizing that both mechanisms co-exist in practice, a formula was developed that encompass both of these mechanisms. In the general dissolution model given in equation (1) diffusivity is expressed by two constants, α and C , as well as the amount of the retarding agent X , that can be used to adjust the dissolution rate.

$$\frac{dQ}{dt} = -A \alpha D_c \quad (1)$$

Where, Q = amount of the drug involved

dQ/dt = dissolution (drug release) rate of the drug

A = surface area of the tablet

αD_c = diffusion coefficient, described by three parameters where

α is a constant and D_c is a function of retarding agent 'X' that expressed as percentage and a constant 'C'

First, the theoretical formula for dissolution is derived for a spherical tablet and using a set of experimental data, the appropriate form of the exponential decay factor of the

diffusivity is examined. Considering the necessity to have sufficient sensitivity to the amount of retarding agent present in the tablet the form of the exponential decay factor of the diffusivity coefficient is selected as is given in equation (2).

$$D_c (X, C) = e^{-C X} \quad (2)$$

Next, the theoretical formula for a cylindrical tablet is derived and verified by applying a number of experimental data. In order to simplify the model used in the predicted dissolution, an 'equivalent radius', *Er0* concept is employed where the initial volume of a given tablet is represented by a spherical tablet of radius *Er0*. Using cylindrical tablet experiment results, it is shown that a common formula can be used to predict the dissolution rates of both cylindrical and spherical tablets. Finally, it is shown that for a given composition, common constant parameters *C* and α can be estimated, for the proposed dissolution rate required from the formula, so that it can adequately describe the dissolution rates of tablets with various amounts of retarding agent as well as the different shapes and initial dimensions.

The bio-equivalence study with twenty healthy adult volunteers was conducted with the above-developed formulation, using a reference theophylline sustained release product (Neulin SR 250 mg, manufactured by 3M pharmaceuticals, Australia). Serum theophylline concentrations were measured by fluorescence polarization immunoassay (FPIA). The SPMC-theophylline extended release tablet formulation developed (Manufactured by the State Pharmaceuticals Manufacturing Corporation), demonstrated that there were no significant difference between regimens with respect to bio-availability and pharmacokinetics (AUC, C_{max} & T_{max}) when the test product was compared with the reference product.

The SPMC-theophylline sustained release tablet 125 mg tablet was registered with the Drug Regulatory Authority of Sri Lanka and the first commercial order worth Rs. 50 million received from the Department of Health Supplies, Sri Lanka by winning a World Wide Open competitive tender. This amply demonstrated the commercial viability and marketability of the new product.

In conclusion all the above mentioned objectives were achieved successfully.